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Telomere length homeostasis is essential for the long-term survival of stem cells, and its set point determines the
proliferative capacity of differentiated cell lineages by restricting the reservoir of telomeric repeats. Knockdown
and overexpression studies in human tumor cells showed that the shelterin subunit TPP1 recruits telomerase to
telomeres through a region termed the TEL patch. However, these studies do not resolve whether the TPP1 TEL
patch is the only mechanism for telomerase recruitment and whether telomerase regulation studied in tumor cells is
representative of nontransformed cells such as stem cells. Using genome engineering of human embryonic stem
cells, which have physiological telomere length homeostasis, we establish that the TPP1 TEL patch is genetically
essential for telomere elongation and thus long-term cell viability. Furthermore, genetic bypass, protein fusion, and
intragenic complementation assays define two distinct additional mechanisms of TPP1 involvement in telomerase
action at telomeres. We demonstrate that TPP1 provides an essential step of telomerase activation as well as
feedback regulation of telomerase by telomere length, which is necessary to determine the appropriate telomere
length set point in human embryonic stem cells. These studies reveal and resolve multiple TPP1 roles in telomere
elongation and stem cell telomere length homeostasis.
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Telomere length in human somatic cells sets a boundary
for their proliferative capacity, allowing the growth and
tissue renewal necessary for the human life span while
restricting excessive malignant growth deleterious to
tissue function (Shay and Wright 2005). During human
embryogenesis, telomere lengths in somatic cell lineages
are established such that they can support a complex de-
velopmental program while remaining short enough so
that telomere attrition can contribute to tumor suppres-
sion in the adult (Aubert 2014). Elucidating the mecha-
nisms that determine stable telomere length homeostasis
and the telomere length set point in embryonic stem cells
is therefore fundamental to our understanding of normal
cellular renewal and its deregulation in cancers. Telomere
maintenance critically depends on the shelterin protein
complexes that protect genome integrity by forming
specialized telomeric chromatin (Palm and de Lange
2008; Cesare and Karlseder 2012). Shelterin protein com-
plexes contain TRF1 and TRF2 bound to double-stranded
telomeric repeats, POT1 bound to single-stranded telo-
meric repeats, and TIN2 and TPP1 bridging these direct
DNA-binding proteins. Compromised shelterin function
can lead to telomere deprotection, activation of DNA
damage responses, and inappropriate genomic rearrange-
ments byDNA repair pathways that ultimately lead to cell
cycle arrest or cell death (Palm and de Lange 2008; Cesare
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and Karlseder 2012). Importantly, in addition to its end-
protective functions, the shelterin complex both negatively
regulates telomere elongation by sequestering the chro-
mosome 39 end from telomerase and stimulates telomere
elongation by recruiting telomerase for new telomeric
repeat synthesis (Nandakumar and Cech 2013).
The interdependence of TPP1, POT1, and other shelterin
components for telomere binding presents a challenge for
dissecting individual protein contributions to telomere
length homeostasis. Depletion and overexpression exper-
iments establish TPP1 and POT1 as negative regulators of
telomere length (Loayza and de Lange 2003; Houghtaling
et al. 2004; Liu et al. 2004; Ye et al. 2004; Hockemeyer
et al. 2007; Churikov and Price 2008; Baumann and Price
2010). Recent studies using protein expression knock-
down suggest that TPP1 also promotes telomerase activ-
ity at telomeres (Lue et al. 2013; Nakashima et al. 2013).
The TPP1 oligonucleotide/oligosaccharide-binding fold (OB)
and specifically an OB surface termed the TEL patch me-
diate the interaction of TPP1 and telomerase assayed by
coimmunopurification of overexpressed proteins from
cell extract, cellular colocalization of overexpressed pro-
teins, and extent of telomere elongation in human tumor
cell lines (Wang et al. 2007; Xin et al. 2007; Abreu et al.
2010; Tejera et al. 2010; Nandakumar et al. 2012; Sexton
et al. 2012; Zhong et al. 2012). Importantly, shelterin
integrity is not detectably compromised by overexpressed
TPP1 that either lacks the OB (DOB) or is mutated in the
TEL patch (Xin et al. 2007; Nandakumar et al. 2012),
establishing that these mutant TPP1 proteins are dis-
rupted specifically for telomerase interaction and not for
TPP1 telomere-protective functions. Previous studies
that tested mutant TPP1 function in human tumor cell
lines relied on substantial overexpression of TPP1 mu-
tants in the presence of residual wild-type protein, and
expression of the wild-type TPP1 increased with time in
culture (Nakashima et al. 2013). Thus, previous studies
have not been able to determine whether telomerase in-
teraction with the TPP1 TEL patch is a genetically ex-
clusive mechanism for human telomerase recruitment to
telomeres or whether telomerase also can act at telo-
meres independently of the TPP1 TEL patch. Indeed,
previous studies suggest secondary recruitment mecha-
nisms for human telomerase dependent on telomere length,
telomerase levels, or whether telomerase is concentrated
in Cajal bodies (Zhao et al. 2011; Stern et al. 2012).
Although overexpressed TPP1 OB alone is sufficient to
localize telomerase to an ectopic site (Zhong et al. 2012),
shelterin protein stoichiometry suggests that the physi-
ological TPP1–telomerase interaction would occur in the
context of the TPP1–POT1 heterodimer (Takai et al. 2010).
Numerous telomerase regulatory activities have been as-
cribed to POT1 based on in vitro enzyme activity assays,
including competition for telomerase binding to single-
stranded DNA or enhancement of telomerase binding to
the same substrates by suppression of guanosine quad-
ruplex structures (Kelleher et al. 2005; Lei et al. 2005;
Zaug et al. 2005). TPP1–POT1 interaction requires the
POT1-binding domain (PBD) within TPP1 and the C
terminus of POT1. Purified recombinant TPP1–POT1 can
stimulate the repeat addition processivity (RAP) of human
telomerase approximately threefold, dependent on the TEL
patch and specific residues in the TERT N-terminal (TEN)
domain (Wang et al. 2007; Zaug et al. 2010; Nandakumar
et al. 2012). Increased RAP is dependent on the addition of
recombinant TPP1–POT1 directly to telomerase activity
assays and the optimal positioning of a POT1–TPP1-
binding site at the primer 59 end (Wang et al. 2007). Thus,
it remains unresolved whether a stable ternary complex of
telomerase, TPP1, and POT1 would compete, facilitate,
and/or change the RAP of telomere elongation.
The interpretation of previous studies that have used
RNAi to deplete shelterin proteins in human tumor cell
lines is limited by not only residual wild-type protein but
also tumor-specific alterations in chromosome number
and the aberrant process of telomerase activation in tu-
mor cells (Kim et al. 1994; Bryan et al. 1998; Nakashima
et al. 2013), which could change the physiological re-
quirements for telomerase access to telomeres. Studies
using mouse models are complicated by their atypically
long telomeric repeat tracts (Kipling and Cooke 1990).
Here, we introduce the use of human embryonic stem cells
(hESCs) to address open questions about physiological
telomere length homeostasis with a rigorous genetic ap-
proach. We show by targeted gene replacement that the
TEL patch of TPP1 is essential for new telomeric repeat
synthesis and that TEL patch-deficient cells phenocopy
the consequences of homozygous disruption of TERT in
hESCs. Unexpectedly, the TEL patch remained essential
even with the bypass of its role in telomerase recruitment,
suggesting that the TEL patch has a second essential role
as a telomerase activator. Moreover, using intragenic com-
plementation, we show that neither of these essential roles
requires a contiguous telomerase–TPP1–POT1 ternary com-
plex with 1:1:1 subunit stoichiometry. Additionally, we
identify a TPP1 mutation distant from the TEL patch that
allows stable telomere maintenance but at a shorter telo-
mere length set point of homeostasis, demonstrating that
TPP1 provides feedback regulation of telomerase action
responsive to telomere length. These genetically defined
requirements for telomerase action in human cells reveal
an unexpected multiplicity of roles for TPP1.
Results
The TPP1 TEL patch is essential for telomere
elongation in hESCs
To conduct a genetic analysis of human TPP1 require-
ments for telomerase action, we used genome-editing
technologies that we previously established for the effi-
cient genetic manipulation of human pluripotent stem
cells (Hockemeyer and Jaenisch 2010; Hockemeyer et al.
2009, 2011). Specifically, we used zinc finger nucleases
(ZFNs) that target the second exon of TPP1 in combina-
tion with a donor plasmid to facilitate homology-directed
repair of the endogenous TPP1 locus in WIBR#3 hESCs.
We used this approach to edit the TPP1 locus to express a
TPP1 variant in which the acidic loop of the TEL patch
(amino acids 166–172) was replaced with a GSSG linker
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(TPP1 DL) (Fig. 1A; Supplemental Fig. 1). Importantly, we
chose to engineer hESCs to carry this entire acidic loop
deletion because it abrogated TPP1–telomerase associa-
tion assayed by overexpression in HEK293T cells beyond
the incomplete inhibition imposed by any previously re-
ported single amino acid substitution (Fig. 1B;Nandakumar
et al. 2012; Sexton et al. 2012; Zhong et al. 2012). In ad-
dition to mutating the TEL patch acidic loop, our TPP1-
editing strategy introduced a GFP tag at the C terminus of
the TPP1 DL variant expressed from the endogenous locus.
Targeting was highly efficient and resulted in heterozy-
gous and homozygous targeted clones in a single targeting
step. The resulting TPP1 DL-GFP protein localized to telo-
meres as determined by chromatin immunoprecipitation
(ChIP) analysis and immunofluorescence microscopy (IF)
(Fig. 1C,D; data not shown). Consistent with previous
experiments showing that the TPP1 OB is dispensable for
the end-protective shelterin functions of TPP1 (Xin et al.
2007), the engineered TPP1 DL-GFP cells did not present
with telomere dysfunction-induced foci (TIFs), proliferated
initially with the same kinetics as the wild-type cells, and
could be passaged synchronouslywith the parental cell line.
The hESC genome-editing approach eliminated endoge-
nous TPP1 expression, allowing long-term telomere length
analysis without the potential for reversion to wild-type
TPP1 expression noted in previous studies (Nakashima
et al. 2013). We analyzed telomere length dynamics over
multiple months of continuous culture of wild-type, het-
erozygous (DL/+), and homozygous (DL/DL) hESCs. Telo-
mere length remained stable in wild-type and heterozygous
DL/+ cells (n = 2 independent cell lines examined) but
progressively decreased in homozygous DL/DL cells (n = 4
independent cell lines examined) (Fig. 2A,B). Initially, TPP1
DL/DL cells proliferated at a wild-type rate, with doubling
times indistinguishable from heterozygous TPP1 DL/+ and
parental hESCs. However, an abrupt decrease in prolifer-
ation was observed over ;2 wk when telomeres reached
2.5–3 kb in average length, and all cells died;90 d after
targeting. Even at very late time points, ;80 d after
targeting, TPP1DL/DL hESC cultures still containedmost-
ly pluripotent cells monitored at the single-cell level for
OCT4 expression by IF (Fig. 2C). However, these OCT4-
positive cells at late time points had a readily detectable
change in nuclear morphology, with lobulated, blebbed
nuclei indicative of cells undergoing apoptosis (Fig. 2C,D).
This increase in numbers of early apoptotic cells was ac-
companied by an increase in dead cells detaching from
TPP1 DL/DL hESC colonies. At 90 d after targeting, the
only TPP1 DL/DL cells remaining in the culture were a
small number of spontaneously differentiated cells, which
are normally observed in hESCs cultures and were not
proliferating and thus did not undergo additional telomere
Figure 1. Establishment of TPP1 TEL patch-deficient hESCs. (A) Targeting schematic for ZFN-mediated editing of human TPP1 using
homology-directed repair to introduce a C-terminally GFP-tagged TPP1 DL allele in the endogenous TPP1 locus. ATG indicates the
endogenous translation start sites encoding TPP1 or TPP1 N as indicated. (E) Exon; (PA) polyadenylation signal. (B) Telomerase primer
extension activity from HEK293T overexpression and Flag immunoprecipitation of F-TPP1 full-length (FL) or OB overexpressed with
zz-TERTand hTR. (RC) Recovery control. (C) ChIP of wild-type (WT) (+/+) or heterozygous (DL/+) or homozygous (DL/DL) TPP1 DL-GFP
cell extracts assayed in duplicate. (D) Quantification of relative levels of telomeric repeat association with GFP normalized to input
telomere signal for results in C. Alu repeat association is shown as a control for immunoprecipitation specificity.
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shortening. Control experiments conducted in parallel
established that telomeres were maintained in cells that
were edited to express the wild-type TPP1-GFP from the
endogenous locus (Supplemental Fig. 1). Furthermore, a
genetic replacement strategy exploiting an inducibly deleted
transgene recapitulated the same loss of telomere mainte-
nance specific to the TPP1 DL/DL genotype (Supplemental
Fig. 1).
These findings are in contrast to murine ESC cultures
that can escape short telomere-induced cell death by ac-
tivation of a telomerase-independent alternative telomere
maintenance pathway (Niida et al. 2000). In the course of
analyzing TPP1 DL/DL hESCs and additional experiments
described below, no telomerase-independent pathway for
survival of proliferating hESCs was observed. We conclude
that in hESCs, telomerase action through the TPP1 TEL
patch is an essential step of telomere maintenance.
TEL patch disruption phenotypes are indistinguishable
from TERT knockout
To test whether TPP1 TEL patch disruption was as severe
as complete loss of telomerase function and/or whether it
imposed a compounded growth phenotype by disrup-
tion of shelterin as well as telomerase function, we
compared the TPP1 DL/DL hESC phenotypes with those
of hESCs lacking active telomerase. We again used ZFN-
mediated genome editing to generate TERT-deficient
(TERT/) WIBR#3 hESCs by integrating a STOP cassette
into the first exon of the TERT gene (Fig. 3A; Sup-
plemental Fig. 2). We then directly compared TERT/
and TPP1 DL/DL cells. While telomerase activity was
readily detectable in the parental hESC extract at a level
comparable with that of immortalized human cell lines
(Supplemental Fig. 2C), homozygous TERT disruption in
several independent clonal lines eliminated telomerase
activity (Fig. 3B; Supplemental Fig. 2D). Homozygous loss
of TERT (n = 3 independent cell lines examined) resulted
in no detectable change of initial proliferation rates com-
pared with TERT+/ hESCs (n = 2 independent cell lines
examined) or the parental line. As expected, TERT/ cell
lines exhibited progressive telomere shortening, while
TERT+/ cell lines retained telomere length maintenance
(Fig. 3C,D). The slight shortening of telomeres in TERT+/
cells compared with parental wild-type cells may derive
from clonal variability rather than TERT haploinsuffi-
Figure 2. The TPP1 TEL patch is essential for telomere maintenance in hESCs. (A) Telomere restriction fragment length assay of wild-
type (WT) or heterozygous or homozygous TPP1 DL-GFP lines over a time course of continuous passaging. (B) Quantification of
telomeric repeat hybridization signal lengths in homozygous TPP1 DL-GFP cell lines as compared with wild-type and heterozygous
TPP1 DL-GFP lines over continuous passaging. (C, top) Phase-contrast images of late time point colony morphology. (Bottom) IF of late
time point hESC colonies stained against OCT4, with magnification of the indicated boxed representative nuclei below. Bar, 200 mm.
(D) Box plot of quantification of nuclear blebbing wild-type or heterozygous or homozygous TPP1 DL-GFP at a late time point.
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ciency in hESCs, as TERT+/ cells could be maintained
in long-term culture (>190 d) with stable telomere lengths
(Supplemental Fig. 2E).
All TERT/ cell lines exhibited reduced proliferation
starting;75 d after the loss of telomerase function. Around
90 d after telomerase loss, corresponding to telomere
lengths of ;2.5–3 kb, proliferating cells were no longer
detectable in the TERT/ hESC cultures. The rate of telo-
mere shortening and the number of post-targeting days of
continuous passage prior to cell death were indistinguish-
able from TPP1 DL/DL lines. Late passage TERT/ cells
also presented the same nuclear blebbing and cell slough-
ing observed for TPP1 DL/DL cells (Fig. 3E,F), thus pheno-
copying the cell death as well as the proliferative limit of
TPP1 DL/DL cells. Similar to the TPP1 DL/DL hESCs,
TERT/ hESCs retained pluripotency until cell death, as
indicated by expression of the pluripotency marker OCT4
(Fig. 3E). Also TERT/ hESCs did not yield any prolifer-
Figure 3. TERT knockout phenocopies TPP1 DL time course of failures in telomere maintenance and cellular renewal. (A) Targeting
schematic for ZFN-mediated integration of a STOP cassette into the endogenous TERT locus. (B) TRAP assay of whole-cell extracts
from independent TERT+/ and TERT/ cell lines (n = 3 each) using 333 ng of total protein. (IC) Internal control. (C) Telomere
restriction fragment length assay of TERT+/ and TERT/ cell lines over a time course of continuous passaging. (D) Quantification of
telomeric repeat hybridization signal lengths in TERT+/ and TERT/ cell lines over a time course of continuous passaging, including
those from B. (E) IF of late time point TERT+/ and TERT/ cell lines stained against OCT4. Bar, 200 mm. Dashed square in the top
panels indicates an individual nucleus for each genotype that is shown magnified in the bottom panel. (F) Box plot of quantification of
nuclear blebbing of late time point TERT+/ and TERT/ cell lines.
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ating survivor cells, with only differentiated cells re-
maining after 90 d, which again phenocopied the late
stage TPP1 DL/DL hESC cultures. In genetic epistasis
experiments, hESCs double-targeted to have the geno-
type of TERT/ and TPP1 DL/DL had proliferation
intervals to cell death and telomere loss (Supplemen-
tal Fig. 2F) that were indistinguishable from hESCs with
either single gene replacement, demonstrating that
the TPP1 TEL patch and telomerase function in the
same genetic pathway. Collectively, these findings dem-
onstrate that the TPP1 DL substitution of wild-type TPP1
does not exacerbate telomere shortening by imposing any
growth-limiting compromise of shelterin but instead se-
lectively and completely eliminates telomerase action at
telomeres.
TPP1 DL or TERT overexpression does not bypass
TEL patch function
Many factors contribute directly or indirectly to telomerase
action at telomeres in human tumor cells, including telo-
merase and shelterin component abundance (van Steensel
and de Lange 1997; Palm and de Lange 2008; Nandakumar
and Cech 2013). Consistent with findings for human tumor
cells, hESC telomere length was influenced by the level of
shelterin component expression (Supplemental Fig. 3A,
B). To investigate whether the telomere maintenance de-
fect in TPP1 DL/DL hESCs can be rescued by increased
expression levels of TPP1 DL or TERT, we exploited ZFN-
mediated targeting for integration of these factors at the
AAVS1 locus. In previous experiments, we established
the AAVS1 site as a safe harbor locus in hESCs that can be
targeted with high efficiency to support robust transgene
expression (Hockemeyer et al. 2009, 2011). We used this
approach in TPP1 DL/DL cells to integrate transgenes di-
recting strong constitutive expression of Flag-tagged TPP1
(TPP1-F), TPP1 DL (TPP1 DL-F), or TERT (Fig. 4A; Supple-
mental Fig. 3). IF confirmed that both TPP1-F and TPP1
DL-F localized to telomeres (Fig. 4B), and immunoblot
analysis confirmed overexpression of TERT from the
AAVS1 locus despitemodest, if any, increase in telomerase
activity assayed in cell extracts (Supplemental Fig. 3C,D).
Analysis of individual clonal cell lines (Fig. 4C) or pooled
cell populations (Fig. 4D) revealed that TPP1-F but not
TPP1 DL-F or TERT overexpression rescued telomere
shortening. With TPP1-F expression, telomeres elongated
and were then maintained at lengths comparable with
telomeres of the parental hESCs (Fig. 4D). Accordingly, ex-
pression of TPP1-F but not TPP1 DL-F or TERT suppressed
nuclear blebbing and cell death in the TPP1 DL/DL cells
(Fig. 4E).
In parallel, we tested the rescue of TPP1 DL/DL cells by
expression of TPP1 lacking the entire OB (TPP1DOB) or
TPP1 N, a TPP1 isoform that carries an N-terminal exten-
sion due to initiation from an alternative endogenous start
site (Fig. 1A). TPP1DOB expression did not forestall telo-
mere shortening or cell death, whereas, like the shorter
TPP1-F, TPP1 N expression led to telomere elongation and
restored cell viability (Supplemental Fig. 3E,F). These find-
ings underscore the genetically essential role of the TEL
patch for telomerase action and telomere maintenance in
hESC.
Telomerase action at telomeres requires activation
through the TPP1 TEL patch
Defects in the physical recruitment of telomerase to
telomeres can be suppressed by direct fusion of TERT to a
telomeric DNA-binding domain or protein (Evans and
Lundblad 1999; Armbruster et al. 2004). To test whether
the telomere maintenance failure of TPP1 DL/DL cells
can be rescued by forcing telomerase physical association
with telomeres, we targeted the AAVS1 locus for inte-
gration of a transgene expressing a TERT fusion with TPP1
DL (TPP1 DL-F-TERT) (Fig. 5A). We also targeted AAVS1 to
express TPP1 DL-F-TERT R132D using TERT with the
TEN domain substitution R132D that preserved telome-
rase catalytic activity but disrupted telomerase recruitment
to telomeres (Stern et al. 2012) and strongly diminished
telomerase association with TPP1 (Fig. 5B). In parallel, we
expressed F-TERT, F-TERT R132D, TPP1-F, and TPP1-F-
TERT (Fig. 5A; Supplemental Fig. 4). All of the fusion
proteins containing TPP1 or TPP1 DL localized to hESC
telomeres (Fig. 5C), and all of the fusion proteins con-
taining TERT or TERT R132D reconstituted telomerase
with high activity, unlike reconstitution with the TERT
G100V substitution (Supplemental Fig. 4A) previously
shown to abrogate TPP1 interaction with telomerase and
telomerase RAP stimulation in vitro (Zaug et al. 2010;
Sexton et al. 2012).
We compared the fusion proteins for their ability to
confer telomere length maintenance to both a homozy-
gous TERT/ cell line and a homozygous TPP1 DL/DL
cell line. Surprisingly, only a fusion protein containing
wild-type TERT (TPP1-F-TERTor TPP1 DL-F-TERT) was
able to rescue telomere length maintenance in TERT/
cells (Fig. 5D, left panel). In contrast TERT/ cells
expressing TPP1 DL-F-TERT R132D had telomere short-
ening indistinguishable from the untargeted TERT/
cells or TERT/ cells expressing F-TERT R132D (Fig.
5D, left panel). For the TPP1DL/DL cells, telomere length
maintenance was rescued by expression of TPP1-F or the
TPP1-F-TERT fusion protein containing intact TPP1 but
not by the fusion protein TPP1 DL-F-TERT or TPP1 DL-F-
TERT R132D (Fig. 5D, middle panel). Taken together,
these findings indicate that a fusion protein, TPP1-F-
TERT, provides TPP1 and TERT function individually,
but protein fusion does not bypass the requirement for
TEL patch function in telomerase action at telomeres.
Thus, the TEL patch of TPP1 plays a telomerase activa-
tion role that remains essential even in cells with TEL
patch-independent telomerase localization to telomeres
by covalent tethering to a telomere protein.
Complementation assays for TPP1 and POT1
coordination
We next tested whether the TPP1 TEL patch functions in
recruitment and activation of telomerase at telomeres
could be bypassed by increasing the accessibility of chro-
mosome 39 ends to telomerase. In previous studies,
Sexton et al.
1890 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on June 26, 2018 - Published by genesdev.cshlp.orgDownloaded from 
increased chromosome 39 end accessibility influenced
telomerase RAP of telomere elongation and also allowed
more than one telomerase-mediated elongation event per
telomere in each cell cycle (Baumann and Price 2010;
Zhao et al. 2011). To investigate whether the TEL patch
would remain essential for telomerase action on more
accessible chromosome 39 ends, we expressed a POT1
variant (POT1 DOB) lacking its N-terminal DNA-binding
OB (Loayza and de Lange 2003; Lei et al. 2004). We tar-
geted the AAVS1 locus to express F-POT1 DOB, which, as
expected, localized to telomeres (Fig. 5C), increased TIF
formation (Supplemental Fig. 4 B,C; Takai et al. 2003;
Hockemeyer et al. 2007), and led to notable telomere
elongation in hESCs with wild-type TPP1 (Supplemental
Fig. 4D). On the other hand, F-POT1 DOB expression in
TPP1 DL/DL cells did not rescue telomere shortening (Fig.
5D, right panel) and did not delay cell death relative to the
TPP1 DL/DL genetic background.
When TPP1 and POT1 are added to telomerase elonga-
tion assays using a primer with a single POT1-binding site
at its 59 end, the TPP1–POT1 heterodimer increases telo-
merase RAP (Wang et al. 2007). To investigate whether a
Figure 4. The essential role of the TPP1 TEL patch is not bypassed by telomere or telomerase protein overexpression. (A) Targeting
schematic of variants introduced at the AAVS1 locus. (B) IF of TPP1-F and TPP1 DL-F in a heterozygous TPP1 DL-GFP background
stained against Flag and TRF1. (C) Telomere restriction fragment length assay of a TPP1 DL-GFP homozygous line with TERT, TPP1-F,
or TPP1 DL-F overexpressed from the AAVS1 locus. Samples from individual clonal cell lines are indicated by brackets, each with two
time points of continuous passaging. (D) Telomere restriction fragment length assay of cell populations from TPP1 DL-GFP cells with
TERT, TPP1-F, or TPP1 DL-F overexpressed from the AAVS1 locus compared with the AAVS1 untargeted (untreated) parental
homozygous TPP1 DL-GFP over a time course of continuous passaging. (E) Phase contrast and IF of late time point hESC colonies
targeted at the AAVS1 locus with the indicated constructs and stained against OCT4. Dashed square in the top panels indicates an
individual nucleus for each genotype that is shown magnified in the panel at the right. Bar, 200 mm.
TPP1 function in telomere length control
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Figure 5. Physical recruitment of TERT to telomeres or increased accessibility of chromosome 39 ends does not bypass the
requirement for TEL patch function in telomerase activation. (A) Schematic of proteins and protein fusions tested for genetic
complementation of homozygous TPP1 DL cells or TERT knockout cells. (B) Telomerase primer extension activity of complexes
purified as indicated by zz-TERT or F-TPP1 after overexpression in HEK293T cells. Immunoblot of input zz-TERT is shown in the top
panels as a loading control. (RC) Recovery control; (IB) immunoblot; (RIgG) rabbit immunoglobulin G. (C) IF of TPP1-F-TERT fusion
proteins, F-POT1DOB, TPP1 DPBD-F, TPP1 OB-F, and TPP1 OBDL-F. White arrowheads indicate robust protein signal colocalization.
Bar, 5 mm. (D) Telomere restriction fragment lengths in TERT/ and TPP1 DL/DL cells expressing the rescue assay proteins and protein
fusions. Note that the same TPP1-F sample is used in the middle and right panels and in Figure 6D. (E) Telomerase primer extension
activity of complexes purified by Flag immunoprecipitation after overexpression in HEK293T cells.
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direct 1:1:1 ternary complex of telomerase, TPP1, and
POT1 is required for telomerase elongation of telomeres,
we targeted the AAVS1 locus of TPP1 DL/DL cells to ex-
press TPP1 DPBD, a TPP1 variant that lacks the POT1
interaction domain (Palm and de Lange 2008). We verified
that TPP1 lacking the PBD had no defect in associating
with active telomerase when overexpressed in human tu-
mor cells (Fig. 5E). Consistent with a failure of TPP1 DPBD
to recruit POT1 to telomeres, cells expressing TPP1DPBD-
F had an increased number of TIFs relative to wild-type
hESCs or cells expressing other forms of TPP1 (Supple-
mental Fig. 4C). Despite the increase in TIFs, TPP1 DL/DL
cells with intragenic complementation by TPP1 DPBD
were rescued for viability in long-term culture. Curiously,
telomere length homeostasis in these cells occurred at a
set point of abnormally short length (Fig. 5D). This result
was unexpected because depletion of POT1 from telomeres
generally leads to extensive telomere elongation (Loayza
and de Lange 2003; Hockemeyer et al. 2005; Churikov
and Price 2008).
The TPP1 OB alone can assemble with telomerase in
human tumor cells, detectable by coimmunopurifica-
tion or IF colocalization, when both telomerase and
TPP1 OB are overexpressed (Sexton et al. 2012; Zhong
et al. 2012). We therefore tested for rescue of telomere
maintenance in TPP1 DL/DL cells by expression of the
TPP1OB alone (Fig. 5A). Neither OB-F nor control OB DL-
F expression in TPP1 DL/DL cells averted cell death or
altered the extent of telomere shortening with prolifera-
tion (Fig. 5D, right panel). Overall, we conclude that
TPP1-mediated recruitment and activation of telomerase
does not require a 1:1:1 stoichiometry of telomerase–
TPP1–POT1 ternary complex assembly but does require
assembly of the TPP1 OB into telomere-localized shel-
terin complexes.
TPP1 regulates telomerase action by length-dependent
telomere feedback
To further investigate TPP1 OB functions beyond its con-
tributions to telomerase recruitment and activation, we
targeted the AAVS1 locus to express additional TPP1-F
variants (Fig. 6A). We made mutations within the TPP1
OB TEL patch beyond the acidic residues of the loop that
were deleted in the DL construct by mutating L212, L183,
and E215 individually. We also substituted L104, which is
on the opposite side of the OB from the TEL patch (Wang
et al. 2007). TPP1 L104A substitution has been shown to
compromise POT1-dependent RAP stimulation in vitro
without reducing TPP1 coimmunopurification of telome-
rase activity from cell extracts (Nandakumar et al.
2012; Sexton et al. 2012). We also mutated TPP1 S111
to S111A or S111R because phosphorylation of this site
was proposed to allow S-phase-specific TPP1–telomerase
interaction (Zhang et al. 2013). In addition, because Akt
phosphorylation was proposed to modulate telomerase–
TPP1 interaction by affecting putative TPP1 homodimer-
ization (Han et al. 2013), we mutated the only consensus
Akt phosphorylation site in TPP1 at S498 to generate
S498A and S498E. The large panel of substitutions
variably reduced TPP1 association with telomerase over-
expressed in HEK293T cells, with the largest loss result-
ing from the L212A TEL patch mutation (Fig. 6B).
We compared the function of TPP1-F proteins with sin-
gle amino acid substitutions by parallel targeting of AAVS1
in the TPP1 DL/DL cells. All of the mutant TPP1 proteins
were similarly overexpressed (Supplemental Fig. 4E) and
colocalized with telomeres by IF as expected (Fig. 6C).
None of them compromised telomerase catalytic activity
as assayed in cell extract (Supplemental Fig. 4F). Expres-
sion of each of the phosphorylation site TPP1 mutants
elongated telomeres and conferred extended proliferation
similarly to expression of wild-type TPP1 (Fig. 6D). Ex-
pression of TPP1 with a substitution of TEL patch E215 or
L183 also led to telomere elongation and rescued cell death,
but telomere lengtheningwas partially compromised com-
pared with that in TPP1 DL/DL cells complemented by
expression of wild-type TPP1 (Fig. 6D). Cells expressing
the TEL patch mutant L212A exhibited telomere short-
ening intermediate between TPP1 DL/DL cells without
complementation and cells rescued by wild-type TPP1
complementation and were delayed for, but not rescued
from, cell death. TPP1 DL/DL cells complemented by ex-
pression of TPP1 with an L104 substitution had a distinc-
tive phenotype combining a rescue of long-term culture
viability with the presence of very short telomeres, similar
in length to those of uncomplemented TPP1DL/DL cells at
the time of culture death (Fig. 6D). Telomeres did not
elongate in cells expressing TPP1 L104 variants despite
similar levels of telomerase activity coimmunopurifica-
tion with TPP1 L104A or L104R compared with TPP1
E215A (Fig. 6B), the latter of which clearly supported telo-
mere elongation (Fig. 6D). The short telomere lengths in
cells expressing TPP1DL and a TPP1 L104 substitution did
not induce TIFs (Supplemental Fig. 4C), suggesting that
TPP1 disrupted for L104 function mediates telomerase ac-
tion at critically short telomeres but only at short telo-
meres, leading to a change in the set point of telomere
length homeostasis.
To investigate whether the TPP1 L104 substitutions
and other TPP1 variants alter the set point of telomere
length homeostasis in a stable manner, we followed
telomere lengths over a time course of passaging. Expres-
sion of TPP1-F in TPP1 DL/DL cells restored telomeres to
a length characteristic for wild-type WIBR#3 hESCs by
;7 wk of continuous post-selection culture (Fig. 7A,B).
The TEL patch mutant TPP1 L183R or E215A supported
slower elongation of telomeres, while cells expressing the
TEL patch mutant TPP1 L212A died within this interval
of culture (Fig. 7A,B). In comparison, the TPP1 L104
substitutions and TPP1 DPBD did not elongate telomeres
yet nonetheless conferred long-term survival (>120 d post-
targeting) with maintenance of short telomeres (Fig. 7A,B).
These findings were independent of the TPP1 DL/DL cell
line, as an independent clonal TPP1 DL/DL cell line
complemented by expression of the same set of TPP1
L104 variants had restored viability with similarly altered
telomere length set point (Supplemental Fig. 4G). This was
also true for TPP1 DL/DL cells complemented with ex-
pression of TPP1 DPBD (Supplemental Fig. 4G). Interest-
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ingly, complementation failed to restore telomere length
(Supplemental Fig. 4G) or rescue cell death if DPBD and an
L104 mutation were combined in the same TPP1 protein,
suggesting that TPP1 L104 and the PBD function in at
least partially distinct parallel pathways. We conclude
that TPP1 is not only an essential mediator of telome-
rase recruitment and activation but also a feedback
regulator of telomerase action that can influence the
homeostasis set point of hESC telomere length mainte-
nance (Fig. 7C).
Figure 6. Intragenic complementation resolves multiple TPP1 roles in telomere length maintenance. (A) Schematic of TPP1 variants
used for overexpression at the AAVS1 locus. (B) Telomerase primer extension activity of telomerase purified by the indicated TPP1-F
after overexpression in HEK293T cells. Relative activity is normalized for background and the recovery control (RC). (C) IF of TPP1-F
variants expressed from AAVS1 in the TPP1 DL-GFP background stained against Flag and TRF1, with AAVS1-expressed GFP cells as
a negative control for the Flag antibody background. (D) Telomere length of TPP1 DL/DL cell lines expressing TPP1 variants. Note that
the same TPP1-F sample is used here and in Figure 5D.
Sexton et al.
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Discussion
A genetic approach to understanding human
telomerase action at telomeres
This study establishes hESCs as a model system for under-
standing the mechanisms governing telomerase action at
telomeres. The tumor cells typically used as model sys-
tems to study telomerase function have aberrant telome-
rase reactivation and relatively short telomeres, whereas
hESCs are constitutively telomerase-positive with a phys-
iological set point for telomere length homeostasis that is
characteristic for cells of the early human embryo (Shay
and Wright 2005; Aubert 2014). We used state-of-the-art
genome-editing technologies to accomplish gene targeting
and safe harbor transgenesis in hESCs, thereby creating cell
lines with nonrevertible genetic changes of wild-type TPP1
and TERT expression. The ability to completely replace
wild-type protein allowed rigorous tests of the biochemical
Figure 7. TPP1 separately determines telomerase ability to act on telomeres and the set point of telomere length homeostasis. (A)
Telomeric restriction fragment length assay of TPP1 intragenic complementation cell lines over a time course of continuous passaging.
(B) Quantification of telomeric repeat hybridization signal lengths. The WT symbol indicates genetically unmodified parental WIBR#3
hESC telomere length. (C) Schematic of TPP1 functions in determining telomerase action at hESC telomeres resolved in this study. The
top schematic (I) depicts the essential function of the TPP1 TEL patch (TELp) in recruiting telomerase. Themiddle schematic (II) depicts
the essential role of the TPP1 TELp in a telomerase activation step. Evidence for this model is derived from the analysis of TPP1 DL/DL
cells complemented with fusion proteins that bypass the TEL patch requirement for telomerase recruitment to telomeres. The bottom
schematic (III) depicts the role of TPP1 in regulating the homeostasis telomere length set point at stable telomere length homeostasis.
Evidence for this TPP1 function is derived from the analysis of TPP1 DL/DL cells complemented with TPP1 L104A or TPP1 DPBD.
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interactions that underlie shelterin and telomerase func-
tion. In addition to gene knockout and transgene-based
rescue, we introduce genetic epistasis and intragenic com-
plementation assays to define the biological functions of
TPP1 in the recruitment, activation, and regulation of
telomerase action in hESCs.
The TPP1 DL allele entirely abrogated telomerase func-
tion without disrupting shelterin-mediated telomere end
protection. The complete loss of telomerase action at
telomeres in TPP1 DL hESCs was inferred from a parallel
analysis of TERT knockout hESCs, which phenocopied the
telomere shortening and cell death observed for TPP1 DL
cells, and a direct epistasis analysis of double-targeted TPP1
DL/DL and TERT/ cells. These and additional experi-
ments provide a previously missing demonstration of the
truly essential role of TPP1 in telomerase recruitment. We
conclude that in hESCs, the only mechanism that allows
telomere extension is telomerase recruitment via TPP1. In
previous overexpression studies, individual TEL patch
amino acid substitutions variably reduced TPP1 coimmu-
nopurification of telomerase activity (Nandakumar et al.
2012; Sexton et al. 2012). Paralleling predictions from these
studies, different single amino acid substitutions of the TEL
patch imposed graded loss of function in hESC telomere
synthesis: Complementation of TPP1 DL by TPP1 L212A
delayed telomere shortening and cell death, while cells
expressing TEL patch E215A or L183A had telomere
elongation intermediate between TPP1 L212A and wild-
type TPP1. In contrast to the TEL patch substitutions,
phosphorylation-deficient TPP1 alleles showed no differ-
ence from wild-type TPP1 function, suggesting that the
role of telomere length control by TPP1 phosphorylation
in hESCs remains to be elucidated.
Progressive telomere shortening leads to hESC death
without induction of telomerase-independent telomere
maintenance
The progressive hESC telomere shortening imposed by
TPP1 TEL patch DL was ultimately lethal, as was the
telomere shortening in TERT knockout hESCs. Unlike
the case for murine ESCs (Niida et al. 2000), we show here
that short telomeres in hESCs did not induce a telome-
rase-independent alternative mechanism for telomere
lengthening. In these cultures, a small population of
nondividing differentiated cells remained alive, while
pluripotent hESCs underwent apoptosis. This does not
necessarily reflect a differentiation-promoting role for cri-
tically short telomeres (Batista and Artandi 2013) but
could rather represent the accumulation of post-mitotic
cells that arises from spontaneous differentiation. Our
studies of dozens of cell lines with inhibition of telomerase
action at telomeres (Supplemental Table 1), each assayed
over months of culture growth, failed to detect any out-
growth of viable cell lines. We therefore conclude that
induction of an alternative telomere-lengthening pathway
in checkpoint-proficient human stem cells is a very rare
event. These findings not only uncover a significant dif-
ference between mouse and human stem cell telomere
biology but are also relevant to the development of telo-
merase inhibition as a therapeutic approach for human
cancer. In contrast to most tumor cells, hESCs have ge-
netically intact DNA damage checkpoints, including p53
and Rb function. Hence, it will be interesting to evaluate
in future studies whether telomerase deficiency combined
with other genetic manipulations could promote telome-
rase-independent telomere maintenance in hESCs.
Three functions for TPP1 in telomerase action
at telomeres
Previous studies of cellular phenotypes due to TPP1 de-
pletion demonstrated roles of TPP1 in shelterin-mediated
protection of telomere integrity, negative regulation of
telomerase through POT1, and telomerase physical and
functional recruitment to telomeric chromatin (Palm and
de Lange 2008; Lue et al. 2013; Nandakumar and Cech
2013). The resolution of distinct TPP1 roles in shelterin
assembly and telomerase action was greatly aided by
discovery of the TEL patch dependence of TPP1 associa-
tion to active telomerase (Nandakumar et al. 2012; Sexton
et al. 2012; Zhong et al. 2012). However, in previous studies,
the background of wild-type TPP1 expression precluded
a determination of whether TPP1 is the exclusive mecha-
nism for telomerase–telomere interaction. In support of
the presence of alternate pathways, telomerase action at
telomeres had a different biochemical specificity depend-
ing on whether it occurred with high or intermediate
repeat synthesis processivity (Zhao et al. 2011) and with
or without Cajal body association (Stern et al. 2012).
Our data demonstrate that the TPP1 TEL patch pro-
vides essential determinants of telomerase action at hu-
man stem cell telomeres (Fig. 7C). TPP1 DL and TERT
R132D, each defective for TPP1–telomerase interaction,
failed to support telomeremaintenance in hESCs (Fig. 7C,
schematic I). The TEL patch remained essential for telo-
mere elongation even when chromosome 39 termini were
liberated by expression of a truncated POT1, indicating
that an increased availability of single-stranded DNA
does not bypass the TEL patch requirement. Surprisingly,
the TPP1 TEL patch remained essential for telomerase
action even if the TEL patch function of telomerase
recruitment was bypassed by expression of a TERT-
TPP1 DL fusion protein. Likewise, the TERT R132D
was not active for telomere elongation even if tethered
to telomeres by covalent fusion with TPP1. Thus, the
TPP1 TEL patch mediates an essential activation of
telomere-bound telomerase (Fig. 7C, schematic II). A
similar separation of telomerase recruitment to and
activation at telomeres was described more than a decade
ago in studies of budding yeast in the demonstration that
Est2p (TERT) physical recruitment to telomeres can
bypass the genetic requirement for Est1p but not Est3p
(Evans and Lundblad 1999). In human cells, telomerase
recruitment and activation by the TPP1 TEL patch may
be coupled through conformational change of the TERT
TEN domain (Nandakumar and Cech 2013).
A third role for TPP1 in telomerase action (Fig. 7C,
schematic III) became evident from intragenic comple-
mentation assays that physically separated TPP1 roles in
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telomerase interaction from its other roles, includingTPP1–
POT1 interaction. TPP1 missing the PBD could comple-
ment TPP1 DL (Fig. 7C, schematic III, middle), indicating
that a 1:1:1 stoichiometry of telomerase with TPP1–POT1
is not necessary for telomere elongation. However, telo-
meres were maintained at very short lengths in cells with
complementation of TPP1 DL and TPP1 DPBD, suggesting
that the ternary POT1–TPP1–telomerase complex may
stimulate telomerase action. In future studies, it will be
exciting to test whether this stimulation is the cellular
manifestation of enhanced telomerase RAP observed in
vitro upon addition of TPP1–POT1 to enzyme activity
assays (Wang et al. 2007). Alternately, the TPP1–POT1
complex could influence telomerase action through amech-
anism other than RAP. The establishment of a new telo-
mere length set point in cells expressing both TPP1 DL and
TPP1 DPBD implies a change in the feedback regulation of
telomerase action at telomeres but not necessarily a change
in the amount of telomeric repeat synthesis per telomere
engagement, since the short telomeres of the new homeo-
stasis set point are stably maintained. We speculate that
POT1 tethered near telomerase by a bridging TPP1 could
promote the initiation of repeat synthesis by orienting the
chromosome single-stranded end toward the telomerase
active site. This mechanismwould differentiate telomerase
activation by TPP1–POT1 bound to an extreme chromo-
some terminus (Fig. 7C) from telomerase–TPP1–POT1
complexes bound internally to duplex telomeric repeats.
The telomerase regulation that requires TPP1 L104 (Fig.
7C, schematic III) can be physically separated from the
essential roles of the TPP1 TEL patch. The TPP1 L104
surface is on the opposite face of the OB from the TEL patch
(Wang et al. 2007), consistent with a role other than direct
TPP1–telomerase interaction. As one possibility, L104 sub-
stitution could affect the accessibility of the TPP1 OB to
telomerase interaction by changing shelterin protein in-
teraction topology. Since most shelterin components are
implicated in telomere length regulation (Palmand de Lange
2008; Stewart et al. 2012), a future key question to address
will be how components of the shelterin complex contrib-
ute to telomerase regulation individually and/or in coordi-
nation. Could shelterin subcomplexes with a distinct
composition have a distinct function and form alternate
higher-order structures? How do shelterin protein com-
plexes change the action of telomerase action to establish
a specific balance of telomere length homeostasis? The
genome-editing approach in hESCs described here provides
genetic tools to address these questions. It will be partic-
ularly fascinating to dissect the genetic distinction be-
tween requirements for telomere length maintenance per
se and the telomere length set point of homeostasis.
Materials and methods
hESC culture
Cell culture was carried out as described previously (Soldner
et al. 2009). All hESC lines were maintained on a layer of in-
activated mouse embryonic fibroblasts (MEFs) in hESC medium
(DMEM/F12 [Invitrogen] supplemented with 15% fetal bovine
serum [Hyclone], 5%KnockOut serum replacement [Invitrogen],
1 mM glutamine [Invitrogen], 1% nonessential amino acids
[Invitrogen], 0.1 mM b-mercaptoethanol [Sigma], penicillin/
streptomycin [Gibco], 4 ng/mL FGF2 [R&D Systems]). Cultures
were passaged every 5–7 d either manually or enzymatically
with 1.5 mg/mL collagenase type IV (Invitrogen) and gravita-
tional sedimentation by washing three times in wash medium
(DMEM/F12 [Invitrogen] supplemented with 5% fetal bovine
serum [Hyclone], penicillin/streptomycin [Gibco]).
ZFN-mediated genome editing
Gene targeting with ZFNs was performed as previously de-
scribed (Hockemeyer et al. 2009, 2011). All cell lines created
for this study are listed in Supplemental Table 1. TPP1 targeted
to the AAVS1 locus was removed with cotransfection of Cre re-
combinase mRNA and NLS-GFP mRNA (Stemgent) using pre-
viously described transfection protocols (Hockemeyer et al. 2009)
followed by sorting of GFP-expressing cells and culture of clonally
derived hESC colonies with verification of LoxP site recombina-
tion by PCR. Targeting of the last exon of the TPP1 genomic locus
was excluded due to the presence of the overlapping immediate
neighboring gene RLTPR, transcribed in the opposite sense as
TPP1.
IF and scoring for nuclear blebbing and TIFs
For analysis by IF, cells were washed with PBS, incubated with
PBS + 0.1% Triton X-100, washed once with PBS (preperme-
ablization), fixed with 3.7% formaldehyde in PBS, permeabilized
with PBS + 0.5% Triton X-100, and blocked with PBS + 0.1%
Triton X-100 with 3% horse serum. Fixed cells were incubated
with antibodies against OCT4 (Abnova), Flag (M2, Sigma), TRF2
(Imgenex), g-H2AX (Millipore), TRF1 (gift of Titia de Lange), and
GFP (Abnova) in blocking solution followed by secondary an-
tibodies. Cells were imaged on a Zeiss Observer.Z1, and images
were processed using Axiovision 4.7.
Scoring of blebbed nuclei was performed single blind. Box
plots show scoring of eight individual colonies per cell line at a
time point;2 wk before death of the homozygous TPP1 DL-GFP
and TERT/ lines. P-values were derived from a TukeyHSD test
performed after significance was determined with an initial
ANOVA. Scoring of TIFs was performed single blind; bar graphs
show scoring of the indicated lines with P-values determined by
Fisher’s exact test.
ChIP, RNA detection, Southern blotting, and telomerase
catalytic activity
ChIP was performed as previously described (Loayza and de
Lange 2003). Protein G-conjugated Dynabeads (Invitrogen) were
used to immunoprecipite antibodies. RNA was detected by blot
hybridization as previously described (Sexton et al. 2012). South-
ern blots for detection of genomic insertions were performed as
previously described (Hockemeyer et al. 2009, 2011). A PCR-
based telomeric repeat amplification protocol (TRAP) assay was
performed as previously described using TSNT (AATCCGTCG
AGCAGAGTTAAAAGGCCGAGAAGCGAT) as an internal con-
trol (Kim et al. 1994). The direct primer extension assay for telo-
merase activity was performed as previously described (Sexton
et al. 2012).
Detection of telomere length
For preparation of genomic DNA, hESC lines were washed with
PBS, removed using 1.5 mg/mL collagenase type IV from a plate
containing a MEF feeder layer, and washed three times in wash
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medium by gravitational sedimentation to minimize contami-
nating MEF cells. Genomic DNA was then prepared as in the
Southern blot protocol. Resuspended genomic DNA was di-
gested with MboI and AluI overnight at 37°C. The resulting
DNA was normalized and run on 0.75% agarose (Seakem ME
agarose, Lonza), dried under vacuum for 2 h at 50°C, denatured in
0.5 M NaOH and 1.5 M NaCl for 30 min with shaking at 25°C,
and neutralized with 1 M Tris (pH 6.0) and 2.5 M NaCl twice for
15 min with shaking at 25°C. Next, the gel was prehybridized in
Church’s buffer (1% BSA, 1 mM EDTA, 0.5M NaP04 at pH 7.2,
7% SDS) for 1 h at 50°C before adding the telomeric probe 32P-
end-labeled (T2AG3)3. The gel was washed three times for 30min
in 43 SSC and once for 30 min in 43 SSC + 0.1% SDS before
exposing on a phosphorimager screen.
While this method removed the vast majority of mouse
feeder cells, the signal from mouse telomeres was dispropor-
tionate to human telomeres due to the amplified relative length
and concentration into a smaller area (Kipling and Cooke 1990).
Because MEF telomeres were size-resolved from human telo-
meres, they did not interfere with analysis of hESC telomere
length.
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